Liquamycin* LA-200* (Canada)

This page contains information on Liquamycin* LA-200* for veterinary use.
The information provided typically includes the following:
  • Liquamycin* LA-200* Indications
  • Warnings and cautions for Liquamycin* LA-200*
  • Direction and dosage information for Liquamycin* LA-200*

Liquamycin* LA-200*

This treatment applies to the following species:
Manufacturer: Zoetis

Oxytetracycline Injection

A long-acting broad-spectrum antibiotic

DIN 02157209

Description

Liquamycin LA-200 oxytetracycline injection is a unique, Pfizer patented formulation containing 200 mg oxytetracycline (as oxytetracycline dihydrate) per mL. It provides sustained antibiotic blood level action over a 3 to 5 day period in cattle and over a 3 to 4 day period in swine following a single treatment. Liquamycin LA-200 injection is a sterile, clear, stable, ready-to-use solution. The freezing point of Liquamycin LA-200 injection is -18 °C.

Sustained Antibiotic Action: Oxytetracycline has long been recognized as the proven drug of choice for the treatment of a wide variety of diseases caused by susceptible gram-positive and gram-negative bacteria. The use of parenterally-administered oxytetracycline in the management of diseases is based on an accurate diagnosis and an adequate course of treatment that normally consists of repeated injections over a three-day period.

There are many instances where a prolonged course of parenteral antibiotic therapy is desirable, but impractical due to the inaccessibility of the animal and extra labour costs associated with daily re-treatment practices. Liquamycin LA-200 injection is ideally suited for use in these instances.

The sustained action of Liquamycin LA-200 injection is believed to be in large part due to a controlled precipitation of oxytetracycline at the injection site. In effect, a depot of oxytetracycline is formed and the drug is absorbed and distributed throughout the body more slowly. Several factors are believed to play a role including: (1) the high concentration of Liquamycin LA-200 injection results in a proportionately smaller area for drug absorption from the site of injection than that of less concentrated formulations; (2) the inherent and unique composition of the formulation allows “limited” and controlled precipitation of the drug to occur. If precipitation was not controlled and too much of the drug precipitated at the injection site, blood levels would be markedly lower, accompanied by severe and long-lasting tissue damage at the injection site.

Liquamycin LA-200 injection provides broad-spectrum effectiveness and sustained antibiotic blood levels from a single intramuscular injection in cattle and swine, or from a single subcutaneous injection in cattle.

Liquamycin* LA-200* Indications

Cattle: For the treatment of bacterial pneumonia, pasteurellosis (associated with the shipping fever complex) and footrot caused or complicated by bacteria susceptible to oxytetracycline, and for the treatment of pinkeye (infectious bovine keratoconjunctivitis) caused by Moraxella bovis.

Swine: For the treatment of bacterial pneumonia caused or complicated by bacteria susceptible to oxytetracycline.

Dosage and Administration

Liquamycin LA-200 injection is designed for intramuscular or subcutaneous administration in cattle, and intramuscular administration in swine at the single dose rate of 1 mL per 10 kg body weight, thus providing 20 mg oxytetracycline per kg body weight.

Animals should be restrained to ensure that treatment can be properly administered. Use sterile equipment and follow aseptic procedures. Each injection should be made using a clean, dry, 16 gauge needle. Subcutaneous injections in cattle should be administered into the neck region, just in front of the shoulder, using a needle 1/2 to 5/8 inches in length. Intramuscular injections should be made deep into the fleshy part of the muscle, preferably in the lateral neck region, using a 1 1/2 inch needle.

To minimize pain and local tissue irritation at the injection site in cattle, it is recommended that the dose be divided and administered into separate injection sites; no more than 10 mL should be injected into any one site.

For young pigs less than 10 kg body weight, it is recommended that they receive a dose of 1 mL per animal. For pigs up to 100 kg body weight, the dose may be injected into one site, but for pigs over 100 kg body weight the dose should be divided to minimize pain and local tissue irritation, and administered into two injection sites.

If clinical improvement is not observed within 48 to 72 hours following injection, the diagnosis should be re-evaluated.

Note: In severe disease cases, treatment with Liquamycin LA-200 injection only, may be insufficient.

Warning

Treated cattle and swine must not be slaughtered for use in food for at least 28 days after the latest intramuscular administration, or for at least 48 days in cattle after the latest subcutaneous administration of this drug. This product must not be used in lactating dairy cattle.

Liquamycin* LA-200* Caution

Occasional sensitivity reactions (anaphylaxis) to oxytetracycline have been known to occur. In such cases, administer epinephrine immediately.

Due to the high concentration and long acting effect, temporary swelling at the injection site may be observed for up to five days following injection.

Warm Liquamycin LA-200 injection to body temperature before administering.

Storage

Store at a temperature between 15 and 30°C.

Presentation: Liquamycin LA-200 injection is available in multi-dose 100 mL, 250 mL and 500 mL vials. The product is ready to use and requires no further preparation.

* Registered trade-mark of Pfizer Products Inc.; Pfizer Canada Inc., licensee.

Pfizer Animal Health, Pfizer Canada Inc., Kirkland QC H9J 2M5

88 0295 0

03598AA

NAC No.: 11980592

ZOETIS CANADA
17,300 TRANS-CANADA HIGHWAY, KIRKLAND, QC, H9J 2M5
Order Desk:   800-663-8888
Technical Services Canada:   800-461-0917
Technical Services USA:   800-366-5288
Website:   www.zoetis.ca
Every effort has been made to ensure the accuracy of the Liquamycin* LA-200* information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-04-11

(web4)